Stay updated on Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial
Sign up to get notified when there's something new on the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page.

Latest updates to the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page
- Check6 days agoChange DetectedThe site revision identifier changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check13 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, indicating access is blocked. This reflects a permission or access issue rather than a change in the underlying study data.SummaryDifference0.5%

- Check20 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the previous study record content with a generic error page. This blocks access to the NCT02938520 study details.SummaryDifference20%

- Check27 days agoChange DetectedThe page revision tag was updated from v3.6.6 to v3.7.0, representing a new version of the page for maintenance or updates.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page now shows a new revision tag: v3.6.6, replacing the previous v3.6.5, indicating a backend/document revision without altering the displayed study details.SummaryDifference0.0%

- Check48 days agoChange Detected2016 ( U.S. NIH Grant/Contract ) was added to the study's identifiers. This indicates NIH funding associated with the trial, but it does not alter the study content or user actions.SummaryDifference0.0%

Stay in the know with updates to Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page.